Amgen Stock News

Let''s review the charts and indicators….AMGN

Stocks are gaining after meandering early in the session. Bond yields also advanced and crude oil dropped to below $89 a barrel

HOG and AMGN both rose after their quarterly updates. KKR fell on earnings news. VLDR rose on a deal with AMZN. EDIT fell after terminating its medical chief.

Shares of Mirati Therapeutics are down significantly today as a consequence of poor quarterly sales of Amgen''s Lumakras (sotorasib) non-small cell lung cancer treatment.

By Leroy Leo (Reuters) – Amgen Inc said on Tuesday it would buy back up to $6 billion of its shares in the first quarter and forecast earnings to more than double by 2030 on the back of strong sales in its biosimilar drugs and other key products.

Amgen plans $6 billion share buyback in Q1, sees earnings doubling by 2030

Here is a look at 10 top tech stocks that were making the biggest moves shortly after Tuesday''s opening bell.

Shares of Amgen Inc. shot up 5.2% in morning trading Tuesday, enough to pace the Dow Jones Industrial Average''s gainers, after the biotechnology company provided a mixed full-year outlook but said it would buy back up to $6 billion worth of stock in the current quarter. The company said it expects 2022 adjusted earnings per share of $17.00 to $18.00, which surrounds the FactSet consensus of $17.65. Revenue for the year is expected to be $25.4 billion to $26.5 billion, which is down 2.2% to up 2.0% from 2021, and is below the FactSet consensus of $26.9 billion. From 2022 through 2030, the company expects a compound annual growth rate (CAGR) for revenue in the mid-single digit percentage range and adjusted EPS CAGR in the high-single to low double-digit range. Regarding the company''s plan to repurchase between $6 billion and $7 billion of shares in 2022, the company said it plans to buy back up to $6 billion of its shares during the first quarter. That would represent up to 4.5% of the company''s market capitalization of $132.40 billion.

U.S. stocks trade Tuesday mixed, with the Dow industrials rising on the back of early moves in Amgen Inc. and Goldman Sachs.

Amgen (AMGN) continues to trade higher in the pre-market on Tuesday after the companys Q4 2021 earnings surpassed Street forecasts yesterday

The post Dow Jones Futures Rise; Drug Giant Pfizer Slides On Earnings appeared on BitcoinEthereumNews.com . Dow Jones futures turned higher Tuesday, following another round of volatile stock market action on Monday. Dow Jones biotech Amgen, along Alpha & Omega Semiconductor and Take-Two Interactive Software, are

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc. (NASDAQ: AXSM ) disclosed in a filing that it reached a settlement with Baudax Bio, Inc. (NASDAQ: BXRX ) with regard to a lawsuit alleging that Axsome''s AXS-07 infringed a couple of patents owned by Baudax. Under the settlement agreement, Baudax is to voluntarily dismiss the lawsuit and Axsome will make a one-time payment of $312,500 to Baudax. Axsome has not incurred any obligation to pay any royalty or other contingent consideration nor has it agreed to any other restriction on its manufacture or distribution of AXS-07. Axsome shares were down 3.01% to $29.60 in premarket trading. Editas Announces Termination Of Chief Medical Office With Immediate Effect Editas Medicine, Inc. (NASDAQ: EDIT ) said in a filing with the SEC that Lisa Michaels'' employment with Editas as its chief medical officer was terminated, effective immediately.

Amgen Inc''s (NASDAQ: AMGN ) Q4 revenues increased 3% Y/Y to $6.84 billion , slightly missing the consensus of $6.88 billion. The increase is driven by increased revenue from the Eli Lilly And Co (NYSE: LLY ) COVID-19 manufacturing collaboration. However, its Product sales decreased 1% globally for the fourth quarter. For FY21, total revenues increased 2% to $26.0 billion. Product sales for the full year were flat versus 2020, Full story available on Benzinga.com

Amgen Inc said on Tuesday it would buy back up to $6 billion of its shares in the first quarter and forecast earnings to more than double by 2030 on the back of strong sales in its biosimilar drugs an

Tech stocks got off to a mixed start again Tuesday morning. The Nasdaq and the S&P 500 traded slightly lower while the Dow Jones industrials traded slightly higher.